Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva reports positive findings from Milprosa study

Teva reports positive findings from Milprosa study

18th April 2013

Teva has announced positive data from a sub-analysis of a phase III clinical trial of Milprosa, an investigational once-weekly luteal phase support solution for women undergoing in vitro fertilisation.

Data from the single-blinded randomised study of 1,297 women showed that Teva's vaginal ring product offered similar levels of effectiveness and safety to daily eight percent progesterone vaginal gel among this patient group.

It was also shown that both options were comparable in terms of multiple pregnancy rates – twins or triplets – and multiple live births.

Milprosa is designed to continuously release a steady dose of micronised progesterone and can support embryo transplantation and early pregnancy through supplementation of corpus luteal function.

Dr Henk Jan Out, vice-president of global clinical development for Teva Women's Health, said: "We believe this data supplements the scientific evidence supporting the efficacy and safety of Milprosa for luteal phase support."

Earlier this month, the company announced the UK launch of generic memantine tablets, a new off-label treatment for Alzheimer's disease based on Lundbeck's branded product Ebixa.ADNFCR-8000103-ID-801573714-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.